Notable Labs is pausing the Phase 2 study of cancer drug Volasertib in leukemia, reducing workforce by 65%, and exploring strategic alternatives to conserve cash. Shares rose 5% after the announcement. Joseph Wagner is the interim CEO, with a search for a permanent CEO ongoing.